Cambridge NeuroScience Inc. said it has received a Phase IIsmall business innovation research grant to search for humanversions of worm genes that program nerve cells to die.
The $500,000 grant from the National Institutes of Health willfund the discovery effort, which the Cambridge, Mass.,company (NASDAQ:CNSI) hopes will lead to agents that cancontrol expression of the genes, and thereby treat a variety ofdegenerative diseases of the brain.
Genes have been identified in a roundworm that control thetiming of death in nerve cells. Mutations in these killer genesallow the nerve cells to live longer than usual.
Degenerative neurological diseases involving cell destructioninclude stroke, diabetic peripheral neuropathy and Lou Gehrig'sdisease (amyotrophic lateral sclerosis).
The company's stock was down 50 cents to $5.25 on Monday. --RF
(c) 1997 American Health Consultants. All rights reserved.